China is currently a bit player in pharmaceuticals, but its potential as a drug developer should not be underestimated.
"The capabilities of China are weak compared not only with the U.S., but also compared with India and Israel," an executive at the China-Singapore Industrial Park in Suzhou told Chemical & Engineering News. "But we're catching up fast."
It has a lot of catching up to do. Currently, there is no single organization in China that can perform all the steps involved in drug discovery. The country is known mainly for supplying mature, commodity-type pharmaceutical ingredients in large volumes.
Drug discovery does take place in China, but mostly at small start-up companies and government labs. Currently, about 100 genuinely innovative drugs are being tested in China, versus about 1000 in the United States.
What holds China's drug-development potential back is that few local drug companies have been inspected and certified by the U.S. Food & Drug Administration. Without such approval, Chinese drug makers can't export generic drugs to the United States, as Indian firms do, and therefore can't earn the large amounts of cash needed to expand internationally or invest in new drug discovery.
Things are changing, however. International drug conglomerates, eager to expand in the local market, are becoming increasingly interested in doing drug research in China.
- In 2002, Denmark's Novo Nordisk set up a 50-person drug-discovery lab in Beijing. It announced recently that it will contribute US$2 million to support diabetes research and discover biopharmaceuticals in partnership with the Chinese Academy of Sciences.
- The Swiss firm Roche set up a wholly owned R&D lab in China in 2004, the first multinational pharmaceutical company to do so.
- Novartis is constructing an R&D facility in Shanghai that it plans to staff with 100 to 150 scientists initially, to grow to 500 after five years.
- Britain's AstraZeneca announced last year that it was planning to spend US$100 million for R&D in China over a three-year period, most of which would go towards construction of a new lab.
There are many benefits to doing such work in China. Clinical trials are cheaper, drugs can be developed faster, and the local market is large and growing rapidly (projected to become the fifth largest for pharmaceuticals in three years' time).
Indeed, The Boston Consulting Group, in a report issued in 2002, stated that "the unmet need for sophisticated drugs is vast in China, and the potential payoff is significant."
It's a country where 100 to 150 million people carry the hepatitis-B virus, according to the report, and where neck and head cancers are more common than anywhere else in the world. Chinese also suffer from many of the same chronic conditions routinely treated in the West, including diabetes, high cholesterol, high blood pressure, arthritis, osteoporosis and depression. More and more, the central government is viewing AIDS as a serious problem as well.
It is also doing its share to spur drug discovery in China. Beijing is in the process of amending its new-drug review process to speed up approvals, and has invested heavily in university and research institute labs.
Facilities such as these, along with local start-ups and the multinationals' research centers are attracting large numbers of scientists from abroad. Most of these are Chinese citizens who have studied and worked overseas and have returned home. Shanghai alone is reported to have roughly 60,000 such scientists.
Sources: Chemical & Engineering News, March 12, 2007; BusinessWeek, August 7, 2006; Boston Consulting Group's 2002 report, "China's Growing Drug Market: Will You Be a Contender?"
(This article has also been posted on Helium.com.)